Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% ...

One in five people diagnosed with metastatic cancer in the Netherlands is still alive three years later, according to new ...

The Head and Neck Cancer Drugs/Therapeutics Market is experiencing substantial growth, valued at USD 4.2 Billion in 2024 and ...

In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear skin at Week 52 in Phase 3 ...

Major clinical trial will prescribe stable dose of diazepam to drug users most at risk of overdose from street supply ...

Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms ...

CytomX Therapeutics, Inc.'s ADC candidate, CX-2051, shows promise in colorectal cancer. Click here to read an analysis of ...

In preclinical experiments, the combination of Trastuzumab PH1 + anti-PD1 outperforms the combination of Kadcyla® + anti-PD1 with a statistically significantly greater rate of Complete Responses (74% ...

Every year, a group of Oregon health care professionals gathers for a grim exercise — reviewing every case in which a mother died during or soon after pregnancy.

Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for first-line treatment of triple-negative breast ...

("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the ...

Q3 2025 Management View CEO Sean Nolan stated, “The recent regulatory clarity and progress we've achieved, which was enabled ...